AI Engines For more Details: Perplexity Kagi Labs You
Asthma Treatment: Zileuton is primarily used for the management of asthma, particularly in cases where symptoms are not adequately controlled by other asthma medications such as bronchodilators or corticosteroids. It works by inhibiting the enzyme 5-lipoxygenase, which is involved in the production of leukotrienes, substances that contribute to inflammation and bronchoconstriction in the airways.
Improvement of Asthma Symptoms: Zileuton helps to reduce inflammation in the airways and decrease bronchoconstriction, leading to improved airflow and relief of asthma symptoms such as wheezing, coughing, chest tightness, and shortness of breath.
Prevention of Asthma Attacks: By reducing airway inflammation and constriction, zileuton helps to prevent asthma exacerbations and reduce the frequency and severity of asthma attacks. It is often used as a long-term maintenance treatment to control asthma symptoms and minimize the need for rescue medications.
Zyflo CR Formulation: Zyflo CR (controlled-release) is an extended-release formulation of zileuton that allows for once-daily dosing, providing continuous asthma symptom control throughout the day. This formulation may improve treatment adherence and convenience for patients.
Adverse Effects: Like any medication, zileuton may cause adverse effects in some individuals. Common side effects include headache, gastrointestinal disturbances (such as nausea, vomiting, diarrhea, and abdominal pain), liver function abnormalities (elevated liver enzymes), and insomnia. These side effects are usually mild to moderate in severity and often resolve with continued use or dose adjustment.
Liver Function Monitoring: Due to the risk of liver toxicity, liver function tests should be performed regularly during zileuton treatment to monitor for signs of liver dysfunction. Patients should be advised to report any symptoms of liver injury, such as jaundice (yellowing of the skin or eyes), dark urine, or abdominal pain, to their healthcare provider promptly.
Drug Interactions: Zileuton may interact with other medications, particularly those metabolized by the cytochrome P450 enzyme system. Concurrent use of zileuton with certain drugs, such as warfarin (an anticoagulant) or theophylline (a bronchodilator), may require dose adjustments or close monitoring to prevent adverse effects or drug interactions.
Contraindications: Zileuton is contraindicated in patients with active liver disease or liver function abnormalities. It should not be used in individuals with a history of allergic reactions to zileuton or any of its components.
Rank | Probiotic | Impact |
---|---|---|
genus | Bifidobacterium | Reduces |
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium bifidum | Reduces |
species | Bifidobacterium breve | Reduces |
species | Bifidobacterium catenulatum | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
species | Veillonella atypica | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
0 | 1 | Akkermansiaceae | family | Decreases |
0 | 1 | Veillonella | genus | Decreases |
0 | 1 | Lacticaseibacillus | genus | Decreases |
0 | 1 | Bifidobacterium | genus | Decreases |
0 | 1 | Lachnospira | genus | Decreases |
0 | 1 | Enterocloster | genus | Decreases |
0 | 1 | Escherichia | genus | Decreases |
0 | 1 | Thomasclavelia | genus | Decreases |
1 | 0 | Akkermansia | genus | Decreases |
0 | 1 | Lacrimispora | genus | Decreases |
0 | 1 | Mediterraneibacter | genus | Decreases |
0 | 1 | Shigella | genus | Decreases |
0 | 1 | Streptococcus | genus | Decreases |
0 | 1 | Bacteroides | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
0 | 1 | Blautia | genus | Decreases |
0 | 1 | Collinsella | genus | Decreases |
0 | 1 | Clostridioides | genus | Decreases |
0 | 1 | Roseburia | genus | Decreases |
0 | 1 | Odoribacter | genus | Decreases |
0 | 1 | Fusobacterium | genus | Decreases |
0 | 1 | Dorea | genus | Decreases |
0 | 1 | Eggerthella | genus | Decreases |
0 | 1 | Clostridium | genus | Decreases |
0 | 1 | Escherichia coli O1:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O139:H1 | no rank | Decreases |
0 | 1 | Escherichia coli O141:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O145:H34 | no rank | Decreases |
0 | 1 | Escherichia coli O15:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O155:H21 | no rank | Decreases |
0 | 1 | Escherichia coli O158:H23 | no rank | Decreases |
0 | 1 | Escherichia coli O16:H48 | no rank | Decreases |
0 | 1 | Escherichia coli O170:H18 | no rank | Decreases |
0 | 1 | Escherichia coli O18ac:H14 | no rank | Decreases |
0 | 1 | Escherichia coli O19:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H4 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H5 | no rank | Decreases |
0 | 1 | Escherichia coli O2:K1:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O20:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O25:H16 | no rank | Decreases |
0 | 1 | Escherichia coli O55:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O68:H12 | no rank | Decreases |
0 | 1 | Escherichia coli O7:H15 | no rank | Decreases |
0 | 1 | Escherichia coli O78:H51 | no rank | Decreases |
0 | 1 | Escherichia coli O80:H26 | no rank | Decreases |
0 | 1 | Escherichia coli O84:H7 | no rank | Decreases |
0 | 1 | Escherichia coli O85:H1 | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Akkermansia | no rank | Decreases |
0 | 1 | Clostridium perfringens A | no rank | Decreases |
0 | 1 | Clostridium perfringens B | no rank | Decreases |
0 | 1 | Clostridium perfringens C | no rank | Decreases |
0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
0 | 1 | Clostridium perfringens D | no rank | Decreases |
0 | 1 | Clostridium perfringens E | no rank | Decreases |
0 | 1 | Escherichia coli O103 | serogroup | Decreases |
0 | 1 | Escherichia coli O111 | serogroup | Decreases |
0 | 1 | Escherichia coli O119 | serogroup | Decreases |
0 | 1 | Escherichia coli O121 | serogroup | Decreases |
0 | 1 | Escherichia coli O145 | serogroup | Decreases |
0 | 1 | Escherichia coli O155 | serogroup | Decreases |
0 | 1 | Escherichia coli O157 | serogroup | Decreases |
0 | 1 | Escherichia coli O177 | serogroup | Decreases |
0 | 1 | Escherichia coli O26 | serogroup | Decreases |
0 | 1 | Escherichia coli O3 | serogroup | Decreases |
0 | 1 | Escherichia coli O43 | serogroup | Decreases |
0 | 1 | Escherichia coli O5 | serogroup | Decreases |
0 | 1 | Escherichia coli O78 | serogroup | Decreases |
0 | 1 | Escherichia coli O86 | serogroup | Decreases |
0 | 1 | Escherichia coli O91 | serogroup | Decreases |
0 | 1 | Escherichia coli H20 | serotype | Decreases |
0 | 1 | Escherichia coli O1:H42 | serotype | Decreases |
0 | 1 | Escherichia coli O1:HNT | serotype | Decreases |
0 | 1 | Escherichia coli O10:H32 | serotype | Decreases |
0 | 1 | Escherichia coli O10:K5(L):H4 | serotype | Decreases |
0 | 1 | Escherichia coli O100:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O103:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O104:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H- | serotype | Decreases |
0 | 1 | Escherichia coli O111:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O111:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O111:NM | serotype | Decreases |
0 | 1 | Escherichia coli O112ab:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O112ac:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O113:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O114:H49 | serotype | Decreases |
0 | 1 | Escherichia coli O118:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H19 | serotype | Decreases |
0 | 1 | Escherichia coli O121:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O123:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O125ac:K+:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O126:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H27 | serotype | Decreases |
0 | 1 | Escherichia coli O127:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O128:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O128ac:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O139:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O145:H28 | serotype | Decreases |
0 | 1 | Escherichia coli O145:NM | serotype | Decreases |
0 | 1 | Escherichia coli O146:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O15:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O150:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O152:H23 | serotype | Decreases |
0 | 1 | Escherichia coli O153:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O156:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H- | serotype | Decreases |
0 | 1 | Escherichia coli O157:H43 | serotype | Decreases |
0 | 1 | Escherichia coli O157:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O157:NM | serotype | Decreases |
0 | 1 | Escherichia coli O16:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O165:H25 | serotype | Decreases |
0 | 1 | Escherichia coli O167:H26 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H21 | serotype | Decreases |
0 | 1 | Escherichia coli O174:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O176:H45 | serotype | Decreases |
0 | 1 | Escherichia coli O177:NM | serotype | Decreases |
0 | 1 | Escherichia coli O2:H6 | serotype | Decreases |
0 | 1 | Escherichia coli O2:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O25:NM | serotype | Decreases |
0 | 1 | Escherichia coli O26:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O26:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O28ac:NM | serotype | Decreases |
0 | 1 | Escherichia coli O29:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O32:H37 | serotype | Decreases |
0 | 1 | Escherichia coli O39:NM | serotype | Decreases |
0 | 1 | Escherichia coli O44:H18 | serotype | Decreases |
0 | 1 | Escherichia coli O45:H2 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16 | serotype | Decreases |
0 | 1 | Escherichia coli O6:H16:CFA/II | serotype | Decreases |
0 | 1 | Escherichia coli O6:K2:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O69:H11 | serotype | Decreases |
0 | 1 | Escherichia coli O7:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O7:K1 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H12 | serotype | Decreases |
0 | 1 | Escherichia coli O78:H4 | serotype | Decreases |
0 | 1 | Escherichia coli O79:H7 | serotype | Decreases |
0 | 1 | Escherichia coli O8:H8 | serotype | Decreases |
0 | 1 | Escherichia coli O81:NM | serotype | Decreases |
0 | 1 | Escherichia coli O83:H1 | serotype | Decreases |
0 | 1 | Escherichia coli O86:H34 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O89m:H9 | serotype | Decreases |
0 | 1 | Escherichia coli O9:H10 | serotype | Decreases |
0 | 1 | Escherichia coli O91:H14 | serotype | Decreases |
0 | 1 | Escherichia coli O91:NM | serotype | Decreases |
0 | 1 | Escherichia coli O99:H6 | serotype | Decreases |
0 | 1 | Escherichia coli ONT:H33 | serotype | Decreases |
1 | 0 | Bifidobacterium longum | species | Decreases |
1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
1 | 0 | Veillonella parvula | species | Decreases |
1 | 0 | Streptococcus salivarius | species | Decreases |
1 | 0 | Lachnospira eligens | species | Decreases |
1 | 0 | Enterocloster bolteae | species | Decreases |
1 | 0 | Bacteroides caccae | species | Decreases |
1 | 0 | Escherichia coli | species | Decreases |
1 | 0 | Thomasclavelia ramosa | species | Decreases |
1 | 0 | Bacteroides ovatus | species | Decreases |
1 | 0 | Akkermansia muciniphila | species | Decreases |
1 | 0 | Bifidobacterium adolescentis | species | Decreases |
1 | 0 | Lacrimispora saccharolytica | species | Decreases |
1 | 0 | [Ruminococcus] torques | species | Decreases |
0 | 1 | Veillonella rodentium | species | Decreases |
0 | 1 | Bifidobacterium breve | species | Decreases |
0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
0 | 1 | Veillonella dispar | species | Decreases |
0 | 1 | Shigella dysenteriae | species | Decreases |
1 | 0 | Bilophila wadsworthia | species | Decreases |
0 | 1 | Shigella flexneri | species | Decreases |
0 | 1 | Veillonella sp. S12025-13 | species | Decreases |
0 | 1 | Escherichia albertii | species | Decreases |
0 | 1 | Veillonella nakazawae | species | Decreases |
1 | 0 | Blautia obeum | species | Decreases |
1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
0 | 1 | Escherichia fergusonii | species | Decreases |
1 | 0 | Collinsella aerofaciens | species | Decreases |
0 | 1 | Veillonella rogosae | species | Decreases |
1 | 0 | Clostridioides difficile | species | Decreases |
0 | 1 | Shigella boydii | species | Decreases |
0 | 1 | Blautia parvula | species | Decreases |
0 | 1 | Veillonella atypica | species | Decreases |
1 | 0 | Roseburia hominis | species | Decreases |
0 | 1 | Bifidobacterium angulatum | species | Decreases |
0 | 1 | Flavonifractor plautii | species | Decreases |
1 | 0 | Odoribacter splanchnicus | species | Decreases |
1 | 0 | Fusobacterium nucleatum | species | Decreases |
1 | 0 | Bacteroides xylanisolvens | species | Decreases |
0 | 1 | Shigella sonnei | species | Decreases |
0 | 1 | Streptococcus sp. LPB0220 | species | Decreases |
0 | 1 | Streptococcus sp. HSISM1 | species | Decreases |
0 | 1 | Escherichia marmotae | species | Decreases |
0 | 1 | Streptococcus vestibularis | species | Decreases |
1 | 0 | Dorea formicigenerans | species | Decreases |
0 | 1 | Bifidobacterium bifidum | species | Decreases |
0 | 1 | Bifidobacterium catenulatum | species | Decreases |
0 | 1 | Escherichia sp. E4742 | species | Decreases |
1 | 0 | Eggerthella lenta | species | Decreases |
0 | 1 | Akkermansia glycaniphila | species | Decreases |
0 | 1 | Akkermansia massiliensis | species | Decreases |
0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
1 | 0 | Streptococcus parasanguinis | species | Decreases |
1 | 0 | Clostridium perfringens | species | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.3 | -0.3 | |
ADHD | 2 | 0 | 0 |
Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
Allergic Rhinitis (Hay Fever) | 0.9 | 2.2 | -1.44 |
Allergies | 3.5 | 1.4 | 1.5 |
Allergy to milk products | 1.1 | 0.6 | 0.83 |
Alopecia (Hair Loss) | 0.2 | 0.2 | |
Alzheimer's disease | 2.3 | 3 | -0.3 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.8 | 0.8 | 1.25 |
Ankylosing spondylitis | 2.7 | 0.4 | 5.75 |
Anorexia Nervosa | 0.5 | 0.8 | -0.6 |
Antiphospholipid syndrome (APS) | 0.8 | 0.1 | 7 |
Asthma | 3.4 | 2 | 0.7 |
Atherosclerosis | 1 | 0.4 | 1.5 |
Atrial fibrillation | 1.4 | 0.9 | 0.56 |
Autism | 3.6 | 4.7 | -0.31 |
Autoimmune Disease | 0.8 | 0.4 | 1 |
Barrett esophagus cancer | 0.6 | 0.1 | 5 |
benign prostatic hyperplasia | 0.4 | 0.1 | 3 |
Biofilm | 1.4 | 1.4 | |
Bipolar Disorder | 0.7 | 0.6 | 0.17 |
Brain Trauma | 0.5 | 0.5 | 0 |
Breast Cancer | 0.6 | 0.6 | |
Cancer (General) | 0.6 | 2.3 | -2.83 |
Carcinoma | 1.4 | 0.7 | 1 |
Celiac Disease | 1.8 | 2.3 | -0.28 |
Cerebral Palsy | 1.3 | 0.3 | 3.33 |
Chronic Fatigue Syndrome | 3.2 | 1.7 | 0.88 |
Chronic Kidney Disease | 2.1 | 1 | 1.1 |
Chronic Lyme | 0.2 | 0.2 | 0 |
Chronic Obstructive Pulmonary Disease (COPD) | 1.8 | 1 | 0.8 |
Chronic Urticaria (Hives) | 1.3 | 0.4 | 2.25 |
Coagulation / Micro clot triggering bacteria | 1 | 0.3 | 2.33 |
Cognitive Function | 0.7 | 0.6 | 0.17 |
Colorectal Cancer | 3 | 1 | 2 |
Constipation | 0.8 | 0.2 | 3 |
Coronary artery disease | 1 | 0.9 | 0.11 |
COVID-19 | 5.1 | 5 | 0.02 |
Crohn's Disease | 3 | 2.1 | 0.43 |
Cushing's Syndrome (hypercortisolism) | 0.1 | -0.1 | |
cystic fibrosis | 0.7 | 0.9 | -0.29 |
d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
deep vein thrombosis | 1.1 | 0.4 | 1.75 |
Denture Wearers Oral Shifts | 1.4 | 1.4 | |
Depression | 5.5 | 4.7 | 0.17 |
Dermatomyositis | 0.1 | 0.3 | -2 |
Eczema | 1.1 | 1.3 | -0.18 |
Endometriosis | 1.5 | 1.3 | 0.15 |
Eosinophilic Esophagitis | 0.1 | 0.6 | -5 |
Epilepsy | 1.8 | 1.1 | 0.64 |
erectile dysfunction | 0.6 | 0.3 | 1 |
Fibromyalgia | 1.1 | 0.4 | 1.75 |
Functional constipation / chronic idiopathic constipation | 2.8 | 1.3 | 1.15 |
gallstone disease (gsd) | 1.3 | 0.6 | 1.17 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.8 | -0.14 |
Generalized anxiety disorder | 1.5 | 1.4 | 0.07 |
giant cell arteritis | 0 | 0 | |
Glioblastoma | 0.1 | -0.1 | |
Gout | 1 | 0.4 | 1.5 |
Graves' disease | 1 | 1.4 | -0.4 |
Gulf War Syndrome | 0.3 | 1 | -2.33 |
Halitosis | 1 | 0.1 | 9 |
Hashimoto's thyroiditis | 1.7 | 1.3 | 0.31 |
Heart Failure | 1.9 | 0.6 | 2.17 |
hemorrhagic stroke | 0.1 | 0.1 | |
Hidradenitis Suppurativa | 0.7 | 0.5 | 0.4 |
High Histamine/low DAO | 0.6 | 0.3 | 1 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.4 | 0.25 |
hyperglycemia | 2 | 1.1 | 0.82 |
Hyperlipidemia (High Blood Fats) | 0.6 | 0.1 | 5 |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 2.3 | 3 | -0.3 |
Hypothyroidism | 0.2 | 0.4 | -1 |
Hypoxia | 0.7 | 0.7 | |
IgA nephropathy (IgAN) | 0.4 | 2.5 | -5.25 |
Inflammatory Bowel Disease | 4.9 | 4.2 | 0.17 |
Insomnia | 1.5 | 1.8 | -0.2 |
Intelligence | 0.8 | 0.8 | |
Intracranial aneurysms | 0.3 | 0.1 | 2 |
Irritable Bowel Syndrome | 4.5 | 2.4 | 0.88 |
ischemic stroke | 2.3 | 0.6 | 2.83 |
Liver Cirrhosis | 3.7 | 2.5 | 0.48 |
Long COVID | 3.7 | 3.5 | 0.06 |
Low bone mineral density | 0.3 | -0.3 | |
Lung Cancer | 0.9 | 0.5 | 0.8 |
Lymphoma | 0.4 | 0.4 | |
Mast Cell Issues / mastitis | 0.6 | 0.3 | 1 |
ME/CFS with IBS | 0.7 | 0.7 | 0 |
ME/CFS without IBS | 0.3 | 0.6 | -1 |
membranous nephropathy | 0.1 | 0.1 | |
Menopause | 1.8 | 0.3 | 5 |
Metabolic Syndrome | 3.1 | 3.6 | -0.16 |
Mood Disorders | 5.9 | 4.3 | 0.37 |
multiple chemical sensitivity [MCS] | 1.4 | 0.1 | 13 |
Multiple Sclerosis | 3.3 | 1.4 | 1.36 |
Multiple system atrophy (MSA) | 0.8 | 0.4 | 1 |
myasthenia gravis | 0.5 | 0.1 | 4 |
neuropathic pain | 0 | 1.1 | 0 |
Neuropathy (all types) | 0.5 | 0.4 | 0.25 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 2.8 | -0.08 |
NonCeliac Gluten Sensitivity | 1 | 0.4 | 1.5 |
Obesity | 4.9 | 3.8 | 0.29 |
obsessive-compulsive disorder | 2.4 | 1.4 | 0.71 |
Osteoarthritis | 1.1 | 0.7 | 0.57 |
Osteoporosis | 1.1 | 1.1 | 0 |
pancreatic cancer | 0.3 | 0.1 | 2 |
Parkinson's Disease | 3.8 | 2.7 | 0.41 |
Polycystic ovary syndrome | 1.4 | 1.1 | 0.27 |
Postural orthostatic tachycardia syndrome | 0 | 0.3 | 0 |
Premenstrual dysphoric disorder | 0.4 | 0.4 | |
primary biliary cholangitis | 0.7 | 0.3 | 1.33 |
Primary sclerosing cholangitis | 1.7 | 0.3 | 4.67 |
Psoriasis | 1.9 | 0.6 | 2.17 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.9 | 1.3 | 1.23 |
Rosacea | 0.7 | 0.1 | 6 |
Schizophrenia | 3.9 | 1.5 | 1.6 |
scoliosis | 0.4 | 0.6 | -0.5 |
Sjögren syndrome | 1.9 | 0.9 | 1.11 |
Sleep Apnea | 0.6 | 0.4 | 0.5 |
Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 0.7 | 0.86 |
Stress / posttraumatic stress disorder | 1.4 | 1 | 0.4 |
Systemic Lupus Erythematosus | 1.5 | 1 | 0.5 |
Tic Disorder | 0.2 | 0.4 | -1 |
Tourette syndrome | 0.4 | 0.1 | 3 |
Type 1 Diabetes | 2.1 | 2.1 | 0 |
Type 2 Diabetes | 3.3 | 3.5 | -0.06 |
Ulcerative colitis | 3.3 | 2.2 | 0.5 |
Unhealthy Ageing | 2.1 | 0.6 | 2.5 |
Vitiligo | 0.8 | 0.5 | 0.6 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]